Acute bronchiolitis
Conditions
Interventions
Patients destined for the intervention group will be submitted to the previously developed Clinical Protocol. The actions will be carried out daily on site, in the morning and/or afternoon, until the
MEDICINE RECONCILIATION STANDARD, 2012): tracking of the registration of pharmacotherapy used in pre-hospital admission
preparation of the pharmacotherapeutic history upon admission using the Best Possible Medication History (BPMH) method of obtaining
review of pharmacotherapy
analysis of unintended discrepancies
classification of discrepancies regarding the potential to cause harm and, later, to complement the assessment of the economic outcomes of this practice, a clinical interview will be carried out to co
E02.319.529.500
Sponsors
Fundação Universidade Federal de Sergipe
Fundação Universidade Federal de Sergipe
Eligibility
Age
No minimum to 12 Years
Inclusion criteria
Inclusion criteria: Patients admitted to hospital; stay in hospital for at least 24 hours; children who are from 0 days to 12 years of age and that the caregiver or guardian signs the Informed Consent Form or the Informed Assent Term
Exclusion criteria
Exclusion criteria: Readmitted patients; those who do not consent to participate; those who are discharged within 24 hours of admission; when counseling is not possible, as stated by the care or patient due to physical or mental restrictions, severity of illness or language restrictions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary Outcome 4: Assess whether the number of readmissions of patients is reduced with the proposed intervention, will be carried out by means of an active search in the medical records at the Medical and Statistical Archives Service (Same) after 3 months of hospital discharge, in order to compare the number of readmissions of patients in the control and intervention groups.;Primary Outcome 1: Assess whether there is a reduction in the severity of the discrepancy by medication history in minor, moderate, severe/potentially risky, which will be evaluated using the error severity scale pre-established by the method of WILLS et al. (2016) and KALB et al (2009).;Primary Outcome 2: Assess for one of the adverse reactions that corresponds to the reduction in potential of a drug reaction disk causing this reaction. This evaluation will be carried out using the method of CORNISH et al. (2005).;Primary Outcome 3 Assess whether the proposed time: of patients reduces with an intervention. It will be evaluated by comparing data from the control and intervention groups. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary Outcome 1: Assess whether the mortality rate is reduced after the intervention. This evaluation will be carried out by the method proposed by Charlson (1997). ;Secondary Outcome 2: Assess whether there is a reduction in lost earnings due to premature death (mortality) and will be assessed by the Charlson Comorbidity Index. | — |
Countries
Brazil
Contacts
Public ContactFernanda Feitosa
Fundação Universidade Federal de Sergipe
Outcome results
None listed